Chromosomal translocation t(8;21)(q22;q22) occurs in about 10% of all cases of acute myeloid leukaemia (AML) and is one of the most frequent chromosomal abnormalities found in AML. 1 This translocation generates the RUNX1/RUNX1T1 (AML1/ MTG8, AML1/ETO) fusion gene, which by itself is not sufficient for full leukaemic transformation, but which supports human haematopoietic stem/progenitor cell self-renewal in vivo as well as leukaemic proliferation and clonogenicity ex vivo.
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Generation of RUNX1/RUNX1T1 may not only be an initiating event in leukaemogenesis, but might also become a leukaemiaspecific target for therapeutic approaches. However, its role in leukaemic persistence in vivo and, in particular, its significance for leukaemic stem cells has not been established yet.
One prerequisite for studying possible functions of RUNX1/ RUNX1T1 in maintaining leukaemia in vivo and the development of therapies targeting this genetic lesion is the availability of suitable animal model systems. Several transgenic and knockin mouse models have been developed to study RUNX1/ RUNX1T1-driven leukaemogenesis in murine haematopoietic cells. 5 However, in vivo studies of RUNX1/RUNX1T1 in the human leukaemic background are currently limited due to a lack of suitable xenotransplantation models, as t(8;21)-positive leukaemic cells including the established cell lines do not or only rarely engraft in Nod/Scid mouse strains. 6 The Rag2 mice leads to the development of an adaptive immune system. 7 We tested this immunodeficient mouse strain in combination with the t(8;21)-positive AML cell line Kasumi-1 to establish a xenotransplantation model for t(8;21)-associated AML. Sublethally irradiated newborn mice received an intraperitoneal injection of 10 6 Kasumi-1 cells. Within 53-55 days, transplanted mice developed swollen abdomen or showed other signs of tumour formation. Postmortem examination revealed mainly solid tumours of 1 cm-1.5 cm in diameter (Figure 1a ) located intraperitoneally. Tumour histology and flow cytometry analyses revealed that the tumours consisted almost exclusively of human myeloid CD45 þ , CD34 þ and CD33 þ cells, which is concordant with the immunophenotype of Kasumi-1 cells (Figures 1b and c and data not shown) . Notably, such extramedullary myeloid tumours (granulocytic sarcomas and chloromas) are found in some 20% of all t(8;21) AML cases. 8 In less than half of the animals, we observed infiltration of the spleen by leukaemic cells, but neither bone marrow nor liver infiltration ( Figure 1c ). Consistent with this, RUNX1/RUNX1T1 protein was strongly expressed in tumours, occasionally and weakly in spleen and never in liver ( Figure 1d ).
We recently analysed the significance of RUNX1/RUNX1T1 for leukaemic proliferation and clonogenicity using short interfering RNAs (siRNAs). A single siRNA treatment caused a transient reduction in fusion protein levels lasting 5-7 days. siRNA-mediated RUNX1/RUNX1T1 depletion restored myeloid differentiation capacity, inhibited proliferation and severely impaired leukaemic clonogenicity in vitro.
3,4 However, these experiments did not address the in vivo significance of this leukaemic fusion protein in human leukaemic cells. To examine the consequences of a transient RUNX1/RUNX1T1 depletion on leukaemic engraftment and tumour formation, we used the Rag2 À/À gc À/À transplantation system. We electroporated Kasumi-1 cells either in the absence of any siRNA ('mock'), with siRNA targeting the RUNX1/RUNX1T1 fusion site ('siAGF1') or with a mismatch control siRNA ('siAGF6') as described previously.
3 siRNA-mediated RUNX1/RUNX1T1 suppression was examined by western blotting and functionally analysed Letters to the Editor by colony formation assays. 4 In comparison to mock and mismatch siRNA-treated cells, siAGF1-treated cells showed at least a threefold decrease in fusion protein and a sixfold decrease in colony forming cells in vitro (Figures 2a and b) . One day after siRNA treatment, cells were either transplanted or stored in liquid nitrogen till transplantation. Transplantations were performed by intraperitoneally injecting 10 6 electroporated cells into sublethally irradiated newborn mice. Total group sizes were 12 animals for the mock group, 11 animals for the active siRNA group and 10 animals for the mismatch control siRNA group. Transplantation of mock-or mismatch siRNAtreated cells resulted in tumour formation in all transplanted animals with a median survival of 50 days (Figure 2c) . In contrast, pretreatment with the active RUNX1/RUNX1T1 siRNA siAGF1 resulted in an extended median survival of 73 days (Po0.02). Notably, three animals of the active siRNA group examined 71 days post-transplantation showed no signs of tumour formation in histological analyses. In a second set of experiments, 2.5 Â 10 5 cells were transplanted 8 h after siRNA electroporation into non-irradiated mice. In this experiment, groups of eight and seven animals were transplanted with active and mismatch siRNA-pretreated cells. This setting resulted in a median survival of 64 and 90 days for the mismatch siRNA and the active siRNA group, respectively. Again, the difference in median survival was statistically significant (Po0.02) suggesting that siRNA-mediated transient reduction of RUNX1/RUNX1T1 causes a substantial decrease in cancer-initiating cells.
In summary, we show that already a transient siRNA-mediated depletion of RUNX1/RUNX1T1 causes a significant increase in median survival in a xenotransplantation model. These findings suggest that RUNX1/RUNX1T1 siRNAs compromises the engraftment and/or self-renewal capacities of t(8;21) leukaemiainitiating cells. Future studies will show whether RNAi-mediated RUNX1/RUNX1T1 suppression during and after leukaemic engraftment may stop or even reverse tumour formation, consequently paving the way for developing therapeutic approaches directly targeting this leukaemic fusion protein. Chronic myeloid leukemia (CML) is a clonal disorder associated with chromosomal translocation t(9;22), which produces the Philadelphia chromosome. 1 The fusion gene encodes for the chimeric oncoprotein BCR-ABL, associated with deregulated constitutive tyrosine kinase (TK) activity, leading to leukemogenesis. 1 Imatinib mesylate, the first potent selective inhibitor of BCR-ABL TK, has become the frontline therapy for newly diagnosed CML patients. 1 A large phase III study (the IRIS study) showed that imatinib can induce complete cytogenetic response (CcyR) in 87% of recently diagnosed patients with CML in chronic phase (CP). 2 Imatinib is also effective in advanced phase disease; however, in general, the response is short-lived. 1 Imatinib has also been incorporated into therapeutic regimens in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph þ ALL). The introduction of imatinib markedly reduced the use of allogeneic hematopoietic stem cell transplantation (SCT) in CML in the first CP. SCT is currently reserved for patients in CP after the failure of imatinib or for patients in advanced phase disease. SCT remains the treatment of choice in patients with Ph þ ALL. Most studies have demonstrated that imatinib therapy before allogeneic SCT does not adversely affect the transplantation outcome and that imatinib can also be used successfully as a bridge to SCT in advanced disease. 3 Resistance to imatinib is an increasingly recognized problem, and it is either primary or acquired. The most common cause for
